Prescribing information



Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.

Hear patients supported by You First discuss the impact the programme has had on their life.




Click here for Cosentyx (secukinumab) prescribing information

You First: Jane’s patient experience

Hear You First patient Jane discussing how the You First programme has supported her to manage her plaque psoriasis.



Click here for Cosentyx (secukinumab) prescribing information

You First: Catherine’s patient experience

You First patient Catherine and You First nurse Sue, discuss the support that the dedicated You First nurse can provide to patients with plaque psoriasis.


CRP, c-reactive protein; DMARD, disease modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate.

Rate this content: 
No votes yet
UK | October 2021 | 154485

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at